Komal Anantrai Dave, PA-C

Komal Dave practices at Texas Oncology PA in Denton, Texas.

Komal Dave's NPI, 1497099709, was assigned on November 27, 2012. Komal Dave holds Texas license PA07657.

Komal Dave's primary practice is Texas Oncology PA, at 2600 Scripture St, Denton, TX 76201 in Denton County. The practice phone is (972) 997-8000.

Komal Dave's primary practice is Texas Oncology PA in Denton, Texas. Komal Dave is also affiliated with Hunt Regional Medical Center Greenville. The medical group on file is Texas Oncology. Dmand AI also links Komal Dave to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Komal Dave practices, 2 sites in all. Vendor and product names are available with a free account.

Physician assistant is Komal Dave's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Komal Dave is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Dmand AI has Komal Dave's licenses on file in 2 states: Texas and Minnesota.

Dmand AI lists tobacco use among the conditions Komal Dave treats.

CMS data shows 223 Medicare services from Komal Dave across 6 procedure codes in 2024, for 165 Medicare patients. Medicare paid $14,318 for them. Every service was in an office.

CMS counts 165 Medicare patients who saw Komal Dave in 2024. The largest group is 65 to 74, with 87 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Komal Dave's median patient age at 65, with 69% women.

In 2024, Komal Dave wrote 239 Medicare Part D claims for 89 patients. 98% of them were for generic drugs. CMS names the drug for 214 of them, across 5 drugs with 11 or more claims each, at $2,656 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Komal Dave for performance year 2024, reported through an alternative payment model (APM). Komal Dave accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Komal Dave as offering telehealth.

CMS Open Payments shows 4 general payments to Komal Dave from 3 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Myriad Genetic Laboratories, Inc. paid the most, $117.